An overview of extended-spectrum beta-lactamases in veterinary medicine and their public health consequences

Authors

  • Diego Borin Nóbrega University of Campinas, Campinas, Brazil
  • Marcelo Brocchi University of Campinas, Campinas, Brazil

DOI:

https://doi.org/10.3855/jidc.4704

Keywords:

antimicrobial therapy, drug resistance, ESBLs, veterinary medicine

Abstract

Serious human and animal infections caused by bacteria are usually treated with beta-lactams. Extended-spectrum beta-lactamases (ESBLs) constitute the most clinically and economically important enzymes that are able to hydrolyze and inactivate beta-lactam antibiotics in veterinary medicine. The spread of ESBLs represents a serious threat to healthcare systems, drastically undermining therapeutic options. The relationship between drug usage and the emergence of resistance has been extensively reported. Nevertheless, the use of antimicrobials in veterinary medicine and the emergence of ESBLs in animals remains a matter of debate. Moreover, there is still controversy about whether antibiotic usage in farm animals poses a potential public health risk. This review will (i) deal with  aspects related to the presence of ESBLs in veterinary medicine, (ii) its link with human medicine, and (iii) discuss strategies to be implemented to preserve antimicrobial effectiveness. New insights relative to old questions concerning antimicrobial use in domestic animals are also presented.

Author Biographies

Diego Borin Nóbrega, University of Campinas, Campinas, Brazil

Department of Genetics, Evolution, and Bioagents

Marcelo Brocchi, University of Campinas, Campinas, Brazil

Department of Genetics, Evolution, and Bioagents

Downloads

Published

2014-08-13

How to Cite

1.
Nóbrega DB, Brocchi M (2014) An overview of extended-spectrum beta-lactamases in veterinary medicine and their public health consequences. J Infect Dev Ctries 8:954–960. doi: 10.3855/jidc.4704

Issue

Section

Reviews